Mevastatin, HMG-CoA reductase inhibitor (ab120652)
Key features and details
- Potent HMG-CoA reductase inhibitor
- CAS Number: 73573-88-3
- Purity: > 98%
- Soluble in ethanol to 10 mM and DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Mevastatin, HMG-CoA reductase inhibitor -
Description
Potent HMG-CoA reductase inhibitor -
Alternative names
- Compactin
-
Biological description
Potent HMG-CoA reductase inhibitor. Proapoptotic, able to arrest cells in G1 by down-regulation of CDK4, CDK6 and cyclin D1 and up-regulation of p21 and p27.
-
Purity
> 98% -
CAS Number
73573-88-3 -
Chemical structure
Properties
-
Chemical name
(2S)-2-Methyl-(1S,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-7-methyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl butanoate -
Molecular weight
390.52 -
Molecular formula
C23H34O5 -
PubChem identifier
64715 -
Storage instructions
Store at +4°C. Store under desiccating conditions. The product can be stored for up to 12 months. -
Solubility overview
Soluble in ethanol to 10 mM and DMSO to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
Source
Synthetic
-
Research areas
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Nucleotide metabolism
- Molecular processes
- Mitochondrial transcription
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipid metabolism
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Cholesterol Metabolism
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Lipoprotein metabolism
- Metabolism
- Pathways and Processes
- Metabolic signaling pathways
- Energy transfer pathways
- Energy Metabolism
- Biochemicals
- Research Area
- Pain & inflammation
- Signaling
- Lipid signaling
- HMG-CoA reductase
- Inhibitors
- Biochemicals
- Research Area
- Alzheimer's Disease
- Signaling
- Lipid signaling
- HMG-CoA reductase
- Inhibitors
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab120652 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Functional Studies |
Use at an assay dependent concentration.
|
| Notes |
|---|
|
Functional Studies
Use at an assay dependent concentration. |
Images
-
Chemical Structure - Mevastatin, HMG-CoA reductase inhibitor (ab120652)2D chemical structure image of ab120652, Mevastatin, HMG-CoA reductase inhibitor
-
Immunocytochemistry/ Immunofluorescence - Mevastatin, HMG-CoA reductase inhibitor (ab120652)ab90529 staining cytochrome C in HepG2 cells treated with mevastatin (ab120652), by ICC/IF. Increase of cytochrome C expression correlates with increased concentration of mevastatin, as described in literature.
The cells were incubated at 37°C for 4 hours in media containing different concentrations of ab120652 (mevastatin) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab90529 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (4)
ab120652 has been referenced in 4 publications.
- Brown M et al. The differential effects of statins on the metastatic behaviour of prostate cancer. Br J Cancer : (2012). PubMed: 22531631
- Yap F et al. Mechanism of AMPK suppression of LXR-dependent Srebp-1c transcription. Int J Biol Sci 7:645-50 (2011). PubMed: 21647332
- Evangelopoulos ME et al. A role of nitric oxide in neurite outgrowth of neuroblastoma cells triggered by mevastatin or serum reduction. Neurosci Lett 468:28-33 (2010). PubMed: 19853642
- Wächtershäuser A et al. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis 22:1061-7 (2001). PubMed: 11408350